
Maravai LifeSciences Holdings, Inc.: updates and filings
Price
$7.07
November 20, 2026Market cap $1.0B
What Ploutos Investor adds for Maravai LifeSciences
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Aug 6, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
August 2026
May 2026
February 2026
November 2025
October 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Financial statements and exhibitsForm8-K
- Sep 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 7, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jun 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 23, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 3, 2026Material agreement entered, material agreement ended, new material financial obligation, Regulation FD disclosureForm8-K
- May 29, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 8, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 24, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 25, 2026Results of operationsForm8-K
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 14, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 7, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 6, 2025Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Financial statements and exhibits | Document |
| Sep 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 7, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jun 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 23, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 3, 2026 | 8-K | Material agreement entered, material agreement ended, new material financial obligation, Regulation FD disclosure | Document |
| May 29, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 8, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 24, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 25, 2026 | 8-K | Results of operations | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 14, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 7, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 6, 2025 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 8, 2020.
The full analysis
What do Maravai LifeSciences's filings show?
The filings are where every one of Maravai LifeSciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.